Want to see JP:6090 full AI Analyst Report?
6090 Stock Chart & Stats
¥715.00
¥1.00(0.16%)
At close: 4:00 PM EST
¥715.00
¥1.00(0.16%)
Day’s Range― - ―
52-Week Range¥570.00 - ¥771.00
Previous CloseN/A
Volume5.70K
Average Volume (3M)10.25K
Market Cap
¥3.55B
Enterprise Value¥1.99K
Total Cash (Recent Filing)¥1.46B
Total Debt (Recent Filing)¥105.06M
Price to Earnings (P/E)16.7
Beta0.28
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.98%
Share Statistics
EPS (TTM)21.53
Shares Outstanding5,919,797
10 Day Avg. Volume8,100
30 Day Avg. Volume10,250
Financial Highlights & Ratios
PEG Ratio-0.95
Price to Book (P/B)1.88
Price to Sales (P/S)2.42
P/FCF Ratio23.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and sizeable equity provide durable financial flexibility for a biotech services firm. This reduces refinancing and solvency risk, supports steady investment in instruments and R&D, and allows the company to pursue partnerships or weather industry cyclicality without forcing dilutive financing.
Revenue Re-accelerationA renewed uptrend in revenue indicates strengthening demand for metabolomics services across pharma, biotech, food and academia. Sustained top-line growth supports scale, better fixed-cost absorption, and longer-term customer relationships that underpin recurring service revenue and platform expansion.
Positive Free Cash FlowConsistent free cash flow above zero enables internal funding for capital expenditure, maintenance of operations, and shareholder returns without dependence on external capital. Over the medium term this supports steady reinvestment in analytical platforms and reduces refinancing sensitivity.
Bears Say
Uneven Cash ConversionVolatile conversion of earnings into operating cash suggests working-capital swings or timing differences that can strain liquidity during growth phases. Persistent uneven conversion complicates budgeting, increases reliance on short-term funding when scaling, and weakens predictability of cash returns to shareholders.
Margin CompressionDeclining margins reduce the firm's ability to convert revenue into sustainable profits and free cash. If driven by pricing pressure, higher input costs, or mix shifts, margin erosion can persistently lower operating leverage and constrain investments in R&D or new service capabilities.
Moderating Returns On EquityA decline in ROE signals reduced efficiency in deploying shareholder capital. If the moderation continues, it could limit long-term shareholder value creation, reflect competitive headwinds, or indicate diminishing incremental returns from recent investments and hamper capital allocation flexibility.
Human Metabolome Technologies, Inc. News
6090 FAQ
What was Human Metabolome Technologies, Inc.’s price range in the past 12 months?
Human Metabolome Technologies, Inc. lowest stock price was ¥570.00 and its highest was ¥771.00 in the past 12 months.
What is Human Metabolome Technologies, Inc.’s market cap?
Human Metabolome Technologies, Inc.’s market cap is ¥3.55B.
When is Human Metabolome Technologies, Inc.’s upcoming earnings report date?
Human Metabolome Technologies, Inc.’s upcoming earnings report date is Nov 06, 2026 which is in 83 days.
How were Human Metabolome Technologies, Inc.’s earnings last quarter?
Human Metabolome Technologies, Inc. released its earnings results on Aug 07, 2026. The company reported ¥6.35 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Human Metabolome Technologies, Inc. overvalued?
According to Wall Street analysts Human Metabolome Technologies, Inc.’s price is currently Overvalued.
Does Human Metabolome Technologies, Inc. pay dividends?
Human Metabolome Technologies, Inc. pays a Annually dividend of ¥18 which represents an annual dividend yield of 2.98%. See more information on Human Metabolome Technologies, Inc. dividends here
What is Human Metabolome Technologies, Inc.’s EPS estimate?
Human Metabolome Technologies, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Human Metabolome Technologies, Inc. have?
Human Metabolome Technologies, Inc. has 5,919,797 shares outstanding.
What happened to Human Metabolome Technologies, Inc.’s price movement after its last earnings report?
Human Metabolome Technologies, Inc. reported an EPS of ¥6.35 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.339%.
Which hedge fund is a major shareholder of Human Metabolome Technologies, Inc.?
Currently, no hedge funds are holding shares in JP:6090
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Human Metabolome Technologies, Inc.
Human Metabolome Technologies, Inc. is a biotechnology company based in Tsuruoka, Japan, established in 2003. It focuses on developing and providing metabolomics technologies and solutions for a range of applications, including drug discovery, disease diagnosis, and food production primarily within Japan. The company offers a comprehensive suite of metabolome analysis services, encompassing global profiling, targeted assays, flux analysis, and lipidomics. Additionally, it develops biomarkers, such as Phosphorylethanolamine, which is measured in blood plasma as a marker for major depressive disorder. HMT's solutions address diverse areas like cancer metabolism, infectious diseases, basic and clinical research, food and nutrition, and microbiome studies. The company also fosters collaborations, notably with the Institute for Advanced Biosciences and Keio University, to further advance metabolome analysis technology.
Technical Analysis
BML
―
Shin Nippon Biomedical Laboratories, Ltd.
―
Cosmo Bio Co., Ltd.
―
―
Perseus Proteomics, Inc.
―